Skip to content

Media / Public health

Approval Is Not Exposure

Why regulatory approval cannot substitute for accumulated human exposure.

Using the contrast between authorized labels and longitudinal safety knowledge, the program separates legal permission, biological exposure, evidence, and informed consent—variables that are often flattened into the single word approved.

Terms in this film

Explore the same term in other films through the transcript glossary.

Continue into the research

Related work

Read the video transcript

Published captions, with their original wording.

We usually treat FDA-approved as a shortcut for safe.

But what happens when labels replace actual medical reasoning?

During a health emergency, compressing complex decisions into a two-word label

severely restricts our options. Take a brand new lethal disease.

By definition, no existing medicine can already possess an approval stamp for it.

Let's map a new proprietary drug on this evidence matrix.

Because a sponsor finances trials, it earns a giant approved stamp on the vertical axis.

But look at the horizontal timeline – accumulated human exposure.

Because the drug is entirely novel, long-term toxicity simply haven't had time to appear.

Now introduce an old, off-patent medicine.

It lacks a sponsor to fund new trials, but its human exposure timeline is completely full,

showing decades of known biological history.

Yet the system slams this old medicine with an unapproved stamp,

making it look biologically disqualified when it actually just lacks a newly funded regulatory

pathway. Here is where the labels become dangerous. Watch the stamps expand.

The approved label drops down to hide the new drug's missing safety timeline,

while the unapproved label covers up the old drug's decades of accumulated knowledge.

The entire complex medical reality gets completely flattened into a false choice.

And this error happens whenever we mistake a funded regulatory stamp for complete biological safety.